(HealthDay News) — Rivaroxaban is associated with reduced risk of recurrent events among patients with venous thromboembolism in equipoise for continued anticoagulation, according to a study published ...

The Food and Drug Administration has given tentative approval to Alembic's rivaroxaban tablets in dosage strengths of 10 mg, 15 mg, and 20 mg. The product is the generic of Janssen’s Xarelto tablets, ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window WASHINGTON -- ...

LOS ANGELES, CA—Another real-world study has suggested that there may be differences among the non-vitamin K antagonist oral anticoagulants (NOACs) in terms of the risk of major bleeding. Among ...

In stable patients hospitalized with COVID-19 and elevated D-dimer levels, therapeutic anticoagulation with rivaroxaban 20 mg once daily did not improve clinical outcomes but did increase bleeding ...

The use of a fixed-dose of rivaroxaban was safe and effective and resulted in an 82% relative risk reduction in the recurrence of venous thromboembolism in patients receiving the drug as part of a ...

The ROCKET-AF trial was designed as double-blind, double dummy trial comparing rivaroxaban (20 mg or 15 mg once a day) with warfarin (target INR of 2.0 to 3.0) for the prevention of stroke and ...

Lower levels of free factor XI and fewer bleeding events seen in patients with atrial fibrillation at moderate-to-high risk for stroke. (HealthDay News) — Subcutaneous injection of abelacimab results ...

Therapeutic-dose anticoagulation primarily consisting of rivaroxaban (Xarelto; Bayer/Janssen), compared with standard thromboprophylaxis, does not improve outcomes in patients hospitalized with ...

August 29, 2012 (Munich, Germany) — Results from the STEMI cohort of the ATLAS ACS 2 TIMI 51 trial have shown similar findings to the overall ACS population, with the 2.5-mg twice-daily dose of ...

The Appraisal Committee considered evidence submitted by the manufacturer of rivaroxaban and a review of this submission by the Evidence Review Group (ERG). The main clinical effectiveness evidence ...